A single institution experience of streptozocin/fluorouracil combination chemotherapy: A case series

J. Naidoo, D. O'Toole, M. J. Kennedy, J. V. Reynolds, M. O'Connor, K. O'Byrne

Research output: Contribution to journalArticle

Abstract

Background The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours. Aim The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period. Method We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient. Result The median progression-free survival was 17 months (range 3-48+ months), and overall survival 31 months (range 12-53+ months) with no toxicity related deaths. Conclusion FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalIrish Journal of Medical Science
Volume181
Issue number2
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Keywords

  • Fluorouracil
  • Metastatic
  • Neuroendocrine
  • Streptozocin
  • Tumour

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A single institution experience of streptozocin/fluorouracil combination chemotherapy: A case series'. Together they form a unique fingerprint.

  • Cite this